I-O Drugs: Key to the Cancer Moonshot?
Checkpoint inhibitor immuno-oncology (I-O) treatments, widely considered as one the most promising breakthroughs in drug development, are a focus of the Cancer Moonshot initiative. But are these new therapies getting reimbursed and what are the challenges they face in gaining market access?
Join us for a live webinar to take a data-driven look at the key challenges facing I-O drugs including:
- Cost and Value
- Interpretation of clinical efficacy evidence
- Restrictions issued by HTA agencies
Ashley Jaksa, MPH
Vice President, Data & Analytics